SLOW-K
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Apr 1975
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SLOW-K is an extended-release oral tablet formulation of potassium, a essential electrolyte used to treat or prevent hypokalemia (low blood potassium levels). The drug works by providing supplemental potassium to restore normal serum levels in patients with potassium deficiency due to diuretics, certain medications, or medical conditions.
LOE Approaching
With LOE approaching and moderate competitive pressure (30%), the brand team is likely focused on generic transition planning and retention strategies rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SLOW-K offers limited growth trajectory but provides valuable experience in managing mature, generic-threatened assets and lifecycle transition strategies. Career progression would likely involve transitioning to pipeline products or taking on broader portfolio responsibilities.
Brand ManagerGeneric Transition Manager
Worked on SLOW-K at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.